source
- Arrowhead’s plozasiran shows favorable safety in severe hypertriglyceridemia late-stage trialsArrowhead presented late-stage data for its RNA interference therapy plozasiran, marketed as Redemplo, in severe hypertriglyceridemia at the European Society of Cardiology 2026 meeting in Munich.…
- BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readoutsBristol Myers Squibb, long recognized for its oncology work, is re‑investing in neurological and psychiatric disease programs, a move rooted in assets gained from its 2019 $74 billion Celgene merge…